During its Q218 results presentation, Bonesupport provided an update on its US commercial platform. It is working to secure distributor contracts so that sales can commence as soon as Zimmer’s exclusivity period ends on 20 October 2018. In Europe, (where all three products are marketed) trauma surgeons are showing strong interest in CERAMENT G and V. Positive outcomes from the CERTiFy (CERAMENT BVF) and FORTIFY (CERAMENT with antibiotics) studies should drive adoption in this large mark
03 Aug 2018
Bonesupport - Taking control of the US market
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bonesupport - Taking control of the US market
BONESUPPORT HOLDING AB (BONEX:OME) | 0 0 0.0%
- Published:
03 Aug 2018 -
Author:
Dr Jonas Peciulis -
Pages:
5
During its Q218 results presentation, Bonesupport provided an update on its US commercial platform. It is working to secure distributor contracts so that sales can commence as soon as Zimmer’s exclusivity period ends on 20 October 2018. In Europe, (where all three products are marketed) trauma surgeons are showing strong interest in CERAMENT G and V. Positive outcomes from the CERTiFy (CERAMENT BVF) and FORTIFY (CERAMENT with antibiotics) studies should drive adoption in this large mark